Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient (Q36265574)

13 August 2017

1 reference

title

Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient (English)

1 reference

13 August 2017

main subject

venous thromboembolism

1 reference

Howard A Liebman

1

1 reference

13 August 2017

publication date

1 September 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

12 Suppl 1

1 reference

13 August 2017

page(s)

11-16

1 reference

Pharmacoeconomics of thrombosis management

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Epidemiology and management of venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Venous tromboembolic treatment in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: a longitudinal study of blood coagulation and fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Venous thrombosis in cancer patients: insights from the FRONTLINE survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Venous thromboembolism in cancer patients: expanding horizons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Fondaparinux: an update on new study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-Fluorouracil-based chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

The management of thromboembolic disease in patients with central nervous system malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073274805012003S03

10.1177/1073274805012003S03

21 January 2018

Identifiers

DOI

0 references

1 reference